% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Neumaier:1006427,
      author       = {Neumaier, Felix and Zlatopolskiy, Boris D. and Neumaier,
                      Bernd},
      title        = {{M}utated {I}socitrate {D}ehydrogenase (m{IDH}) as {T}arget
                      for {PET} {I}maging in {G}liomas},
      journal      = {Molecules},
      volume       = {28},
      number       = {7},
      issn         = {1420-3049},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {FZJ-2023-01662},
      pages        = {2890},
      year         = {2023},
      note         = {This work was supported by Deutsche Forschungsgemeinschaft
                      (DFG), grant number NE 890/9-1.},
      abstract     = {Gliomas are the most common primary brain tumors in adults.
                      A diffuse infiltrativegrowth pattern and high resistance to
                      therapy make them largely incurable, but there are
                      significantdifferences in the prognosis of patients with
                      different subtypes of glioma. Mutations in
                      isocitratedehydrogenase (IDH) have been recognized as an
                      important biomarker for glioma classification anda potential
                      therapeutic target. However, current clinical methods for
                      detecting mutated IDH (mIDH)require invasive tissue sampling
                      and cannot be used for follow-up examinations or
                      longitudinalstudies. PET imaging could be a promising
                      approach for non-invasive assessment of the IDH statusin
                      gliomas, owing to the availability of various mIDH-selective
                      inhibitors as potential leads for thedevelopment of PET
                      tracers. In the present review, we summarize the rationale
                      for the developmentof mIDH-selective PET probes, describe
                      their potential applications beyond the assessment of theIDH
                      status and highlight potential challenges that may
                      complicate tracer development. In addition,we compile the
                      major chemical classes of mIDH-selective inhibitors that
                      have been described to dateand briefly consider possible
                      strategies for radiolabeling of the most promising
                      candidates. Whereavailable, we also summarize previous
                      studies with radiolabeled analogs of mIDH inhibitors
                      andassess their suitability for PET imaging in gliomas.},
      cin          = {INM-5},
      ddc          = {540},
      cid          = {I:(DE-Juel1)INM-5-20090406},
      pnm          = {5253 - Neuroimaging (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5253},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {37049661},
      UT           = {WOS:001001567200001},
      doi          = {10.3390/molecules28072890},
      url          = {https://juser.fz-juelich.de/record/1006427},
}